Show Summary Details

Quick Reference

n. a recombinant monoclonal antibody fragment used for the treatment of wet age-related macular degeneration. It inhibits vascular endothelial growth factor and therefore choroidal neovascularization. Ranibizumab is injected into the eye; the most common side-effects are conjunctival hemorrhage, eye pain, floaters, increased intraocular pressure, and intraocular inflammation. Pegaptanib (Macugen) has similar uses and effects. Trade name: Lucentis.

Subjects: Clinical Pharmacology and Therapeutics.

Reference entries

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.